ASCO: Agent May Be NSCLC 'Game Changer'
CHICAGO (MedPage Today) -- Patients with advanced, mutated non-small cell lung cancer had a 70% response rate to an investigational therapy, including tumors resistant to an agent that targets the mutation, results of a preliminary study showed.
Source: MedPage Today Pulmonary - Category: Respiratory Medicine Source Type: news
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Respiratory Medicine | Study